J&J's ACUVUE OASYS MAX 2-Week Lenses Get CE Mark; Axogen Buys BioCircuit for $200M
JNJ sits 53% above its 52-week low of $173.33 on light trading volume (0.2× avg).
Summary
Johnson & Johnson received CE Marking for its ACUVUE OASYS MAX 2-Week contact lenses, expanding its eye care portfolio in Europe with launch later this year. This follows a series of positive regulatory and clinical developments for J&J, including the FDA De Novo authorization for OTTAVA robotic system in July. The news is part of a broader weekly roundup that also highlights Axogen's $200M acquisition of BioCircuit Technologies and positive clinical data from Roivant, AstraZeneca, and Structure Therapeutics. For J&J, the CE Mark is a modest but incremental positive, reinforcing its diversified healthcare pipeline. Traders may note the stock closed down 0.27% on Thursday, suggesting limited immediate market reaction to this specific approval.
At the time of this announcement, JNJ was trading at $265.90 on NYSE in the Life Sciences sector, with a market capitalization of approximately $640.8B. The 52-week trading range was $173.33 to $281.07. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: dpa-AFX.